Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial

Hepatology · Published 2026-05-01 · DOI 10.1097/hep.0000000000001774

Authors being retrieved — see the publisher record. https://doi.org/10.1097/hep.0000000000001774

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2026

Related articles

Nucleos(t)ide withdrawal vs Nucleos(t)ide withdrawal with adjuvant pegylated-interferon in HBeAg-negative hepatitis B virus infection (NUC-B Trial) · Hepatology · 2026 · Same journal
AASLD-EASL Delphi consensus statement on surrogate endpoints and real-world evidence in primary biliary cholangitis · Hepatology · 2026 · Same journal
Bile acids as the silent harbinger: Early signals of portal hypertension after “successful” Kasai · Hepatology · 2026 · Same journal
Context-dependent STAT3 signaling in liver fibrosis · Hepatology · 2026 · Same journal
Buying time: Therapeutic plasma exchange as a bridge to transplant in acute-on-chronic liver failure · Hepatology · 2026 · Same journal
Two decades of hepatitis E in solid organ transplantation: From endemic insight to unresolved therapeutic questions · Hepatology · 2026 · Same journal
H4K12 lactylation drives TREM2high macrophages differentiation in liver fibrosis · Hepatology · 2026 · Same journal
Diabetes, male sex, low levels of HBsAg, HDV RNA, and ALT predict spontaneous HDV suppression in chronic hepatitis D · Hepatology · 2026 · Same journal
AASLD AST NASPGHAN Practice Guideline on pediatric liver transplantation: Candidate evaluation · Hepatology · 2026 · Same journal
Seeing the scar in higher resolution: AI-derived collagen phenotypes redefine fibrosis in MASLD · Hepatology · 2026 · Same journal